A study by Sadri et al. using [64Cu]Cu-DOTA-cetuximab on breast cancer xenografts with high levels of EGFR demonstrated efficient tumor specificity (confirmed with a blocking study in vivo), achieving a tumor-to-blood ratio of approximately 2 (2 h post-injection). This evidence concerns the gene EGFR and breast carcinoma.